Mo

Molybdenum

Vitamins & Minerals

What is Molybdenum?

Molybdenum is an essential trace mineral that functions as a cofactor in the form of molybdopterin (molybdenum cofactor, Moco) for four important enzymes in humans: sulfite oxidase (converts toxic sulfite to sulfate), xanthine oxidase (catalyzes the final steps of purine degradation, producing uric acid), aldehyde oxidase (metabolizes various drugs and endogenous aldehydes), and mitochondrial amidoxime reducing component (mARC, involved in nitric oxide metabolism and drug metabolism). Of these, sulfite oxidase is considered the most physiologically critical, as its absence leads to the most severe clinical consequences.

Molybdenum is widely distributed in the food supply, with legumes (particularly lentils, peas, and beans), grains, nuts, and organ meats being the richest sources. Absorption in the small intestine is highly efficient (40–100%), and homeostasis is maintained primarily through renal excretion, which adjusts rapidly to dietary intake. Clinical deficiency is extraordinarily rare in humans and has been conclusively documented only in a single patient on prolonged molybdenum-free parenteral nutrition and in the rare genetic disorder molybdenum cofactor deficiency. Blood and urine molybdenum measurements are available but rarely clinically indicated.

Why It Matters

Molybdenum's most critical role is enabling sulfite oxidase to detoxify sulfite to sulfate. Sulfite is generated during the metabolism of sulfur-containing amino acids (methionine, cysteine) and is also present in foods and wines as a preservative. Without functional sulfite oxidase, sulfite accumulates to toxic levels, causing severe neurological damage. Xanthine oxidase is clinically relevant because it produces uric acid—the end product of purine metabolism and the molecule that accumulates in gout. Medications like allopurinol and febuxostat work by inhibiting xanthine oxidase. Aldehyde oxidase metabolizes numerous pharmaceutical drugs, making molybdenum indirectly relevant to drug metabolism and pharmacology.

Normal Reference Ranges

GroupRangeUnit
Adults (serum)0.1–3.0µg/L
Adults (urinary excretion)10–300µg/day

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High Mo Levels Mean

Common Causes

  • Occupational exposure (mining, metallurgy)
  • Environmental contamination near mining operations
  • Very high supplemental intake

Possible Symptoms

  • Gout-like symptoms (elevated uric acid production via xanthine oxidase)
  • Joint pain and swelling
  • Possible reproductive effects at very high exposures (animal data)
  • Gastrointestinal distress

What to do: Molybdenum toxicity from dietary sources is rare. The tolerable upper limit is 2,000 µg/day for adults. If elevated from occupational exposure, reduce or eliminate exposure and monitor uric acid levels, as excess molybdenum can increase uric acid production. Treat gout-like symptoms as appropriate. For environmental contamination, consult occupational or environmental health specialists.

What Low Mo Levels Mean

Common Causes

  • Molybdenum cofactor deficiency (rare autosomal recessive genetic disorder)
  • Prolonged molybdenum-free parenteral nutrition (single documented case)
  • Extremely rare dietary deficiency in regions with very low soil molybdenum

Possible Symptoms

  • Molybdenum cofactor deficiency: severe neonatal seizures, feeding difficulties, lens dislocation (ectopia lentis), progressive neurological deterioration
  • Acquired deficiency (TPN case): tachycardia, tachypnea, night blindness, irritability, coma
  • Sulfite accumulation (elevated urinary sulfite)
  • Low uric acid levels (impaired xanthine oxidase function)

What to do: Acquired dietary molybdenum deficiency is virtually nonexistent in humans eating any reasonable diet. Molybdenum cofactor deficiency is a devastating genetic condition with limited treatment options; cyclic pyranopterin monophosphate (cPMP) replacement therapy has been approved for type A deficiency if administered early. For the single reported acquired case (TPN-related), supplementation with ammonium molybdate resolved symptoms. Ensure parenteral nutrition formulations contain trace amounts of molybdenum.

When Is Mo Testing Recommended?

  • When molybdenum cofactor deficiency is suspected in neonates with seizures and low uric acid
  • In occupational health screening for molybdenum-exposed workers
  • Rarely indicated for nutritional assessment in clinical practice
  • When evaluating unexplained low uric acid levels
  • In research settings studying trace mineral metabolism

Frequently Asked Questions

Molybdenum deficiency is rare for several reasons: it is widely distributed in the food supply, particularly in plant-based foods; the daily requirement is very small (45 µg/day for adults); intestinal absorption is highly efficient (40–100% bioavailability); and the kidneys efficiently adjust excretion to maintain balance. The combination of ubiquitous dietary availability, tiny daily requirements, excellent absorption, and effective renal conservation makes it virtually impossible to become deficient through diet alone. The only clearly documented acquired case occurred in a patient receiving prolonged total parenteral nutrition that lacked molybdenum.
Molybdenum cofactor deficiency (MoCD) is a rare autosomal recessive genetic disorder that prevents the body from synthesizing molybdopterin, the organic molecule that binds molybdenum to create the functional cofactor. Without this cofactor, sulfite oxidase, xanthine oxidase, and aldehyde oxidase are all nonfunctional. The most devastating consequence is sulfite accumulation, which causes severe and progressive brain damage. Affected infants typically present within the first week of life with intractable seizures, feeding difficulties, and progressive encephalopathy. Type A MoCD can now be treated with cyclic pyranopterin monophosphate (Nulibry/fosdenopterin) if diagnosed and treated very early.
Yes, there is a well-established antagonistic interaction between molybdenum and copper, particularly in ruminant animals. In cattle, high dietary molybdenum combined with sulfur forms thiomolybdates in the rumen, which tightly bind copper and prevent its absorption, leading to copper deficiency ("teart" pastures). In humans, this interaction is less clinically significant at normal dietary intakes, but tetrathiomolybdate has been investigated as a pharmaceutical agent to treat Wilson disease (copper overload) by binding excess copper. This therapeutic application leverages the natural copper-antagonizing property of molybdenum-sulfur compounds.

Related Biomarkers

UAUric AcidFeSerum IronCuCopperZnZinc

Want your Mo levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.

Disclaimer: SymptomGPT is not a medical diagnosis tool and does not provide medical advice. Always consult a qualified healthcare professional. If you are experiencing a medical emergency, call 911 immediately.